Home Other Building Blocks Benzenamine, 4-(5-fluoro-2-benzothiazolyl)-2-methyl-

Benzenamine, 4-(5-fluoro-2-benzothiazolyl)-2-methyl-

CAS No.:
260443-89-8
Catalog Number:
AG002RHJ
Molecular Formula:
C14H11FN2S
Molecular Weight:
258.3139
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
1mg
≥98%
1 week
United States
$91
- +
5mg
≥98%
1 week
United States
$161
- +
10mg
≥98%
1 week
United States
$248
- +
25mg
≥98%
1 week
United States
$491
- +
Product Description
Catalog Number:
AG002RHJ
Chemical Name:
Benzenamine, 4-(5-fluoro-2-benzothiazolyl)-2-methyl-
CAS Number:
260443-89-8
Molecular Formula:
C14H11FN2S
Molecular Weight:
258.3139
MDL Number:
MFCD06407710
IUPAC Name:
4-(5-fluoro-1,3-benzothiazol-2-yl)-2-methylaniline
InChI:
InChI=1S/C14H11FN2S/c1-8-6-9(2-4-11(8)16)14-17-12-7-10(15)3-5-13(12)18-14/h2-7H,16H2,1H3
InChI Key:
IFWLHIIUGSEKKE-UHFFFAOYSA-N
SMILES:
Fc1ccc2c(c1)nc(s2)c1ccc(c(c1)C)N
NSC Number:
703786
Properties
Complexity:
302  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
258.063g/mol
Formal Charge:
0
Heavy Atom Count:
18  
Hydrogen Bond Acceptor Count:
4  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0
Molecular Weight:
258.314g/mol
Monoisotopic Mass:
258.063g/mol
Rotatable Bond Count:
1  
Topological Polar Surface Area:
67.2A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
3.8  
Literature
Title Journal
Aryl Hydrocarbon Receptor Ligand 5F 203 Induces Oxidative Stress That Triggers DNA Damage in Human Breast Cancer Cells. Chemical research in toxicology 20150518
Reduction of aromatic and heterocyclic aromatic N-hydroxylamines by human cytochrome P450 2S1. Chemical research in toxicology 20130617
Synthesis and biological evaluation of novel triazoles and isoxazoles linked 2-phenyl benzothiazole as potential anticancer agents. Bioorganic & medicinal chemistry letters 20120901
Bioactivation of fluorinated 2-aryl-benzothiazole antitumor molecules by human cytochrome P450s 1A1 and 2W1 and deactivation by cytochrome P450 2S1. Chemical research in toxicology 20120820
CYP2S1 and CYP2W1 mediate 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW-610, NSC 721648) sensitivity in breast and colorectal cancer cells. Molecular cancer therapeutics 20111001
Variations in Mre11/Rad50/Nbs1 status and DNA damage-induced S-phase arrest in the cell lines of the NCI60 panel. BMC cancer 20110101
The role of aryl hydrocarbon receptor and crosstalk with estrogen receptor in response of breast cancer cells to the novel antitumor agents benzothiazoles and aminoflavone. International journal of breast cancer 20110101
2-(4-Amino-3-methylphenyl)-5-fluorobenzothiazole is a ligand and shows species-specific partial agonism of the aryl hydrocarbon receptor. Toxicology and applied pharmacology 20090515
Preclinical toxicokinetic evaluation of phortress [2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole lysylamide dihydrochloride] in two rodent species. Pharmacology 20090101
Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC cancer 20090101
BRCA1 transcriptional activity is enhanced by interactions between its AD1 domain and AhR. Cancer chemotherapy and pharmacology 20081101
BRCA1 modulates sensitivity to 5F-203 by regulating xenobiotic stress-inducible protein levels and EROD activity. Cancer chemotherapy and pharmacology 20080901
Mechanisms of acquired resistance to 2-(4-Amino-3-methylphenyl)benzothiazole in breast cancer cell lines. Breast cancer research and treatment 20080701
Drug-induced expression of nonsteroidal anti-inflammatory drug-activated gene/macrophage inhibitory cytokine-1/prostate-derived factor, a putative tumor suppressor, inhibits tumor growth. The Journal of pharmacology and experimental therapeutics 20060801
Anti-tumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces single-strand breaks and DNA-protein cross-links in sensitive MCF-7 breast cancer cells. Cancer chemotherapy and pharmacology 20060701
Structural studies on bioactive compounds. 40.(1) Synthesis and biological properties of fluoro-, methoxyl-, and amino-substituted 3-phenyl-4H-1-benzopyran-4-ones and a comparison of their antitumor activities with the activities of related 2-phenylbenzothiazoles. Journal of medicinal chemistry 20060629
BRCA1 modulates xenobiotic stress-inducible gene expression by interacting with ARNT in human breast cancer cells. The Journal of biological chemistry 20060526
Microsphere-based protease assays and screening application for lethal factor and factor Xa. Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501
Differential gene expression as a potential classifier of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole-sensitive and -insensitive cell lines. Molecular pharmacology 20060301
Antitumor benzothiazoles. 26.(1) 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines. Journal of medicinal chemistry 20060112
The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF-kappaB activity in drug-sensitive MCF-7 cells. Anti-cancer drugs 20050201
Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells. Drug metabolism and disposition: the biological fate of chemicals 20041201
In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles. Molecular cancer therapeutics 20041201
The experimental antitumor agents Phortress and doxorubicin are equiactive against human-derived breast carcinoma xenograft models. Breast cancer research and treatment 20040901
The development of the antitumour benzothiazole prodrug, Phortress, as a clinical candidate. Current medicinal chemistry 20040401
Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: a potential surrogate marker for patient sensitivity. Molecular cancer therapeutics 20031201
Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole. Molecular pharmacology 20030301
DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells. British journal of cancer 20030224
Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo. British journal of cancer 20030210
In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles. British journal of cancer 20020422
Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles. Molecular cancer therapeutics 20020201
Antitumor benzothiazoles. 16. Synthesis and pharmaceutical properties of antitumor 2-(4-aminophenyl)benzothiazole amino acid prodrugs. Journal of medicinal chemistry 20020131
Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles. Journal of medicinal chemistry 20010426
Properties